Key Dates for AIM Delisting
Retrieved on:
Thursday, January 6, 2022
EMA, Lists of diseases, COVID-19, AIM, Acromegaly, Degenerative disease, Review, ADS, Company, Environment, Patient, Citibank, Common stock, Forward-looking statement, Diet, ADSS, American depositary receipt, Lipodystrophy, Metreleptin, Stifel, FDA, Press Corporation Limited, NOMAD, EB, Birth, SDRT, GL, Investment, Lomitapide, Octreotide, Pharmaceutical industry, Security (finance), Financial adviser, Communications satellite, Dietary supplement, Junctional epidermolysis bullosa (medicine), EU, Nasdaq
As previously announced, the last day of trading in the Company's Ordinary Shares on AIM will be January 10, 2022 and the proposed AIM Delisting will be effective from 7.00 a.m. (London time) on January 11, 2022.
Key Points:
- As previously announced, the last day of trading in the Company's Ordinary Shares on AIM will be January 10, 2022 and the proposed AIM Delisting will be effective from 7.00 a.m. (London time) on January 11, 2022.
- Following the AIM Delisting, the Company's ADSs will remain listed, and will only be tradeable, on Nasdaq.
- Following the AIM Delisting, Shore Capital and Corporate Limited will cease to act as nominated adviser to the Company.
- The below expected timetable for the AIM Delisting is unchanged from that announced on November 22, 2021.